Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002904:Chromosomes, Human, 21-22 and Y; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013156:Splenectomy; D013866:Thioguanine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D013866:Thioguanine; D002066:Busulfan; D006918:Hydroxyurea; D003630:Daunorubicin